Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Anticancer drug development is complex and multi-factorial, demanding robust drug evaluative architecture in experimental and preclinical studies. To increase the number of drug licensing, biochemical, pharmacological, technical and economic changes (balance and integration) in evaluative systems should be focused in labs throughout the world. Despite great progress, treatment breakthroughs and drug industry need new ideas and more competitive technology (new generation of test systems). Overall, drug evaluative systems comprise anticancer drug development (medicinal chemistry and pharmacology) from initial screening to clinical validity. Its advances greatly impact the outcomes of drug production (rates of final drug licensing and efficacy of therapeutics in the clinic). In this regard, creative ideas and new techniques will change the norm and convention of drug screening and mechanic exploration in the future. This article provides multi-disciplinary approaches for experimental and preclinical anticancer drug evaluations, selections and combinations (chemistry and biomedicine). Future trends for drug evaluative systems are especially highlighted in in-depth, multilateral and multidisciplinary approaches.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180819666220610102444
2024-04-01
2025-06-15
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180819666220610102444
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test